Here is a summarized version of the content in 200 words:
Intake, a South Korean company specializing in precision fermentation food technology, has secured $9.2 million in Series C funding from seven institutional investors, led by CJ Investment. This brings the company’s total funding to $20 million. Founded in 2013, Intake has developed yeast-based solutions for sustainable protein sources, with revenue increasing 30% to $15.2 million in 2024. The funding will be used for R&D, global infrastructure expansion, and commercialization of microbial-based alternative proteins. Intake’s patented yeast strain boasts 1.5 times the protein content of conventional yeast, positioning it to tap into the $35 trillion global protein market. The company is also developing Hemeprotein, a flavor component traditionally derived from meat and egg albumin, through precision fermentation. Intake is committed to advancing microbial-based alternative food technologies to provide consumers with healthy and environmentally-friendly options. With this funding, the company aims to finalize its core microbial-based alternative food technologies and establish itself as a leader in the alternative food sector.